At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Progesterone for the Management of Preterm, Premature Rupture of the Membranes: A Randomized Controlled Trial.
In Brief
A Phase 2 clinical trial evaluating 17-Hydroxyprogesterone Caproate and Caster Oil injections for Pregnancy Complications. Completed, enrolled 21 participants across 2 sites.
Detailed Summary
Preterm birth is the leading cause of neonatal death and a significant cause of life long disability and health problems. It has been shown that the drug 17-hydroxyprogesterone caproate can help reduce the risk of preterm delivery in women with certain risk factors for preterm birth. We hope to learn whether this same medication can be used to prolong pregnancy in a group of patients in whom this medication has not been previously studied. Specifically, we hope to learn whether progesterone supplementation will delay delivery in women with pre-term, premature rupture of membranes (PPROM).
Study Details
Timeline
Interventions
Weekly injections of 17-hydroxyprogesterone caproate.
Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.